Samih Darwazah Tops Scrip Emerging Markets Leaders

Amman, 17 December 2013 – Hikma Pharmaceuticals (LSE:HIK) (NASDAQ Dubai: HIK), is pleased to announce that its Founder and Chairman, Mr Samih Darwazah, was selected as the first Emerging Markets Leader of the Scrip 100 list.

Press Release Corporate 17 December 2013

The list recognizes company heads that are shaping the future of pharma in their respective countries and includes a number of significant emerging market pharmaceutical leaders such as Bill and Melinda Gates for the Gates foundation, Takeda’s Head of Commercial Operations, and the CEO of Samsung Biologics.

The Scrip 100 is a list of the top 100 leaders in the pharmaceutical business compiled by the Scrip editorial team. The top 100 leaders selected include philanthropists, regulators and company heads that have shaped the future of pharma in their countries with a global view of the biopharmaceutical industries.

Further details can be found on

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.